Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Mucositis 1Meningioma 1

Interventions

Magnetic Resonance Spectroscopy 12gallium Ga 68 dotatate 6Everolimus 6lutetium Lu 177 dotatate 5Radiosurgery 5Proton Therapy 5Bevacizumab 5pembrolizumab 4Surveys and Questionnaires 4Specimen Handling 4Hydroxyurea 4abemaciclib 3Tranexamic Acid 3Surgical Procedures, Operative 3Sodium Chloride 3Ga(III)-DOTATOC 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vistusertib 2trametinib 2ribociclib 2arginyllysine 2aldesleukin 2Yoga 2Whole Body Imaging 2Sunitinib 2Saline Solution 2Ropivacaine 2Radiotherapy 2Protons 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Meningioma × Lysine × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡